Avidity Biosciences, Inc.
Clinical trials sponsored by Avidity Biosciences, Inc., explained in plain language.
-
Three-Year extension trial tests promising muscle disease treatment
Disease control CompletedThis study followed patients who completed an earlier trial to evaluate the long-term safety and effectiveness of AOC 1001, an experimental treatment for myotonic dystrophy type 1. Thirty-seven adults with this genetic muscle disease received intravenous doses every 8 weeks for u…
Phase: PHASE2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Apr 04, 2026 05:07 UTC
-
First human trial tests potential new treatment for rare muscle disease
Disease control CompletedThis study tested the safety and effects of a new drug called AOC 1001 in adults with myotonic dystrophy type 1, a genetic muscle-wasting disease. Thirty-nine participants received either the drug or a placebo through an IV to see how their bodies handled it and if it affected th…
Phase: PHASE1, PHASE2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC